Last-Chance drug gets Real-World review
NCT ID NCT07278921
Summary
This study looks back at medical records to see how well a drug called mosunetuzumab worked for adults with a type of blood cancer called follicular lymphoma that had come back or didn't respond to at least two previous treatments. The drug was given through a special program for patients who had run out of standard options. Researchers want to know how long patients lived without their cancer getting worse and what side effects they experienced.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Ospedale San Raffaele
RECRUITINGMilan, 20132, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.